Sulopenem-Etzadroxil/Probenecid + Ciprofloxacin
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Uncomplicated Urinary Tract Infections
Conditions
Uncomplicated Urinary Tract Infections
Trial Timeline
Aug 1, 2018 → Jan 20, 2020
NCT ID
NCT03354598About Sulopenem-Etzadroxil/Probenecid + Ciprofloxacin
Sulopenem-Etzadroxil/Probenecid + Ciprofloxacin is a phase 3 stage product being developed by Iterum Therapeutics for Uncomplicated Urinary Tract Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT03354598. Target conditions include Uncomplicated Urinary Tract Infections.
What happened to similar drugs?
1 of 5 similar drugs in Uncomplicated Urinary Tract Infections were approved
Approved (1) Terminated (0) Active (4)
🔄Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg + Phenazopyridine Hydrochloride Tables, USP 200 mgAmneal PharmaceuticalsPhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03354598 | Phase 3 | Completed |
Competing Products
13 competing products in Uncomplicated Urinary Tract Infections
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ZY19489 + Ferroquine (FQ) + Placebo | Zydus Lifesciences | Phase 1 | 36 |
| KLU156 + Coartem | Novartis | Phase 3 | 40 |
| Artemether-lumefantrine (COA566) | Novartis | Phase 2/3 | 38 |
| INE963 | Novartis | Phase 2 | 35 |
| KAE609 + SoC (Coartem) + KLU156 | Novartis | Phase 2 | 35 |
| KAF156 + Coartem + Lumefantrine Solid Dispersion Formulation | Novartis | Phase 2 | 35 |
| INE963 + KAE609 (Cipargamin) + SoC (Coartem) + KLU156 | Novartis | Phase 2 | 42 |
| KAF156 + LUM-SDF + Coartem | Novartis | Phase 2 | 35 |
| Co-artemether | Novartis | Approved | 43 |
| Broncho-munal® + Placebo | Sandoz Group | Phase 3 | 37 |
| Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg + Phenazopyridine Hydrochloride Tables, USP 200 mg | Amneal Pharmaceuticals | Phase 3 | 37 |
| Peramivir + Placebo | BioCryst Pharmaceuticals | Phase 2 | 29 |
| solithromycin + ceftriaxone + azithromycin | Allergy Therapeutics | Phase 3 | 34 |